The debate over the effectiveness of Chinese COVID-19 vaccines in preventing infections may be entering a new stage as infection rates rise steadily in countries that have predominantly relied on jabs made by Sinopharm and Sinovac.
Critics argue that some Chinese vaccine phase 3 clinical trials have shown efficacy rates to be barely above 50%, as was the case with Sinovac in Brazil. They say that explains the resurgence of the virus in some countries, even though large percentages of these populations have received injections.
- Get a daily email packed with the latest China-Africa news and analysis.
- Read exclusive insights on the key trends shaping China-Africa relations.
- Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.